Results 21 to 23 of about 42 (23)

The impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS

Rheumatology Science and Practice
Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess
L. P. Ananyeva, A. Lila, I. Gaydukova, D. Abdulganieva, M. Starovoytova, G. V. Lukina, A. A. Porozova, A. Eremeeva, P. P. Pukhtinskaia, E. L. Nasonov   +9 more
semanticscholar   +1 more source

The efficacy and safety of divozilimab in real-world clinical practice

Neurology, neuropsychiatry, Psychosomatics
   Objective:  to evaluate the efficacy and safety of divozilimab, a humanised anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (MS) in real-world clinical practice.    Material and methods.
Sh. R. Nabiev, I. Oganesyan, S. A. Dzhukkaeva, Sh. D. Yusifzade, O. Voskresenskaya   +4 more
semanticscholar   +1 more source

MSR169 Predicting Outcomes and Estimating Minimum Sample Sizes for Divozilimab Efficacy in NMOSD: A Clinical Trial Simulation and Unanchored Matching-Adjusted Indirect Comparison

Value in Health
Olga Mironenko, K. Sapozhnikov, Andrei Lazarev, D. Tolkacheva, N. Sableva, A. Zinkina-Orikhan, Anastasiia Porozova   +6 more
semanticscholar   +1 more source